Opto-p53: A light-controllable activation of p53 signaling pathway
Cell Structure and Function · 2025 · 50 (1) · 145-156
DOI: 10.1247/csf.25017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Structure and Function, 2025. Verfasst von Tatsuki Tsuruoka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Quantitative Biology, National Institute for Basic Biology, National Institutes of Natural Sciences. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Signal Transduction, Light, Optogenetics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Quantitative Biology, National Institute for Basic Biology, National Institutes of Natural Sciences.
- Quantitative Biology Research Group, Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences.
- Department of Basic Biology, School of Life Science, SOKENDAI (The Graduate University for Advanced Studies).
- Laboratory of Cell Cycle Regulation, Graduate School of Biostudies, Kyoto University.
- Center for Living Systems Information Science, Graduate School of Biostudies, Kyoto University.
Zitieren
APA
Tsuruoka, T., Goto, Y., & Aoki, K. (2025). Opto-p53: A light-controllable activation of p53 signaling pathway. Cell Structure and Function, 50(1), 145-156. https://doi.org/10.1247/csf.25017
Vancouver
Tsuruoka T, Goto Y, Aoki K. Opto-p53: A light-controllable activation of p53 signaling pathway. Cell Structure and Function. 2025;50(1):145-156. doi:10.1247/csf.25017
BibTeX
@article{Tsuruoka2025,
author = {Tsuruoka, Tatsuki and Goto, Yuhei and Aoki, Kazuhiro},
title = {Opto-p53: A light-controllable activation of p53 signaling pathway},
journal = {Cell Structure and Function},
year = {2025},
volume = {50},
number = {1},
pages = {145--156},
doi = {10.1247/csf.25017}
}
EUVIMED